Plain-English translation of NCT07179783 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications— and —to treat two particularly aggressive forms of prostate cancer that no longer respond to hormone-blocking drugs. These two cancers, called aggressive variant prostate cancer and neuroendocrine prostate cancer, tend to grow very quickly and are hard to treat. Researchers believe that combining these two medications may help control the disease better than current standard treatments.
Right now, there is no standard, proven treatment plan for these aggressive types of prostate cancer—doctors typically use chemotherapy based on guidelines for other cancers. Early research suggests that combining immunotherapy with chemotherapy may work better, but this needs to be tested in patients to see if it's safe and effective.
You likely qualify if…
You likely don't qualify if…
You would receive injections or infusions of the two medications on a regular schedule at a hospital or clinic. You would need to attend regular visits for blood tests, imaging scans, and physical exams to check how the cancer is responding and watch for side effects. The trial is enrolling about 28 patients total, and you would be monitored closely throughout your treatment to ensure the medications are working and are safe for you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China